Data as of Dec 11
| +0.10 / +6.67%|
The 1 analysts offering 12-month price forecasts for Boston Therapeutics Inc have a median target of 1.95, with a high estimate of 1.95 and a low estimate of 1.95. The median estimate represents a +21.87% increase from the last price of 1.60.
The current consensus among 1 polled investment analysts is to Buy stock in Boston Therapeutics Inc. This rating has held steady since November, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.